Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

Supernus Pharmaceuticals ebit from 2011 to 2025. Ebit can be defined as earnings before interest and taxes.

Supernus Pharmaceuticals EBIT 2011-2025 | SUPN

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

Supernus Pharmaceuticals ebit from 2011 to 2025. Ebit can be defined as earnings before interest and taxes.

Related Stocks
Company Name	Market Cap
Teva Pharmaceutical Industries (TEVA)	$15.5B
Dr Reddy's Laboratories (RDY)	$11.4B
BridgeBio Pharma (BBIO)	$6.4B
Bausch Health Cos (BHC)	$1.9B
Amphastar Pharmaceuticals (AMPH)	$1.1B
Personalis (PSNL)	$282M
Taysha Gene Therapies (TSHA)	$254M
Assembly Biosciences (ASMB)	$75M
Sol-Gel Technologies (SLGL)	$15M
Evoke Pharma (EVOK)	$3M
Teligent (TLGT)	$0M